We often get questions about #PreApproval access #EarlyAccess #ManagedAccess #CompassionateUse #NamedPatientProgram) and #UnlicensedMedicines.
Follow the link read to read our Q&A with @StuartBMAC, @InceptuaGroup: inceptua.com/inceptua-qa-wha…
#pharmaindustry #biotech #drugs
Don't forget to register for the free webinar on Monday the 14th of December with expert speakers from @pfizer and Inceptua on Strategic #ComparatorSourcing in #China. #chinesemarket #pharma #clinicalsupply.
xtalks.com/webinars/strategi…
1
How to optimize your oncology clinical trial supply?
Learn more here: inceptua.com/oncology
#oncology #clinicaltrials #comparatorsourcing #pharma #biotech #CRO
Jeremy Broadis and @ME_Corbett are attending #bioeurope digital, October 26-29. Don't hesitate to reach out and get in touch to discuss launch partnerships for Europe or global pre-approval access #partnerships #specialtycare #rarediseases #earlyaccess
Inceptua - Pharma Company and Service Partner retweeted
Replying to @InceptuaGroup
@InceptuaGroup receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion hubs.li/H0x2k370 #Jetrea #vitreolysis #treatment #EC
Inceptua participated in an initiative to raise awareness of the challenges of access to treatment for patients suffering from #rarediseases: healthawareness.co.uk/rare-d…. Don't hesitate to connect with @StuartBMAC and reach out with any questions you may have. #earlyaccess
1
Information to our Medicines Access Clients - follow our updates on inceptua.com/covidupdate-med…
5
Access our latest webinar #ondemand inceptua.com/industry-trends… and learn more about #ExpandedAccess as a Key Component in the #Drugdevelopment and #Launch Process #preapprovalaccess
We anticipate three key trends for #comparatorsourcing in #China: 1. continued action against low quality and counterfeited products, 2. improved quality of local generics, and 3. a focus on lower costs. Learn more by following the link, and go to page 68: lnkd.in/d_6YJF2
Welcome the more than 280 people across the industry who have already registered to join our webinar, February 20 (3PM London/10AM New York), on #expanded access as a key component in the development and launch process. You still have the chance to join: business-review-webinars.com…
LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – Inceptua and @portola_pharma have entered into an agreement whereby Inceptua will become Portola’s exclusive distribution partner for Ondexxya® in selected countries:
inceptua.com/inceptua-and-po…
1
1
Welcome to our new Head of Asia Pacific, #clinicaltrial Services, Philip Gregory. Read the full press release here: inceptua.com/inceptua-appoin…
2
Thanks to everyone attending the @Expanded_Access Summit and the session on 'The Integration of #EarlyAccess into Treatment and Clinical Research' with Inceptua’s @StuartBMAC. Don't miss our free webinar, February 20 Click here to register: https://nitter.cf/t.co/g6T2K9l1is
1
"Across #rarediseases (...) we share the same goal: Getting treatments to patients in need (...). In Europe it can take up to 1100 days for an #orphandrug to become available (...) Make treatment available faster through pre-approval access (...)." @ME_Corbett, #WODC2019.
Inceptua - Pharma Company and Service Partner retweeted
Welcoming back the incomparable Stuart Bell, PhD to discuss the latest innovation in pragmatic trial design for #ExpandedAccess Jan. 27-29, 2020 easummit.net/
Jeremy Broadis and Sarah Fry are attending #BIO2019 in Philadelphia to discuss how we can help get rare disease therapies to patients in need. DM us if you’d like to discuss opportunities further.
#medicinesaccess #preapproval #orphandrugs #helpingpharmahelpingpatients #pharma
1
Inceptua - Pharma Company and Service Partner retweeted
Brilliant @JAMAOnc paper on single patient use #expandedaccess at @mskcc by Hyman et. al. 36.1% of products were in Phase 2, 39.4% in Phase 3, and an incredible 18.8% were in Phase 1. Authors call for routine prospective collection of efficacy data in expanded access. Fully agree



















